Table 2. Base-case analysis.
Strategy | Cost, US$ |
Incremental cost, US$ | Effectiveness, QALYs | Incremental QALYs | ICER, US$/QALY gained | Effectiveness, LYs | Incremental LYs | ICER, US$/LY gained |
---|---|---|---|---|---|---|---|---|
No screening | 2.18 | - | 24.94580 | - | - | 24.94807 | - | - |
HTLV-1 antenatal screening | 76.85 | 74.67 | 24.94766 | 0.00186 | 40,100 | 24.94813 | 0.00006 | 1,245,303 |
HTLV-1, human T cell leukemia virus 1; QALY, quality-adjusted life-year; LY, life expectancy life-year; ICER, incremental cost-effectiveness ratio